(trifluoromethyl)phenyl]methanone; PME, particle mesh Ewald; POPC, 1-palmitoyl-2-oleoyl-snglycero-3-phosphocholine; TM, transmembrane; VCP171, (2-amino-4-(3-(trifluoromethyl)phenyl)thiophen-3-yl)(phenyl)methanone; WT, wild-type.
This article has not been copyedited and formatted. The final version may differ from this version. there is a relative paucity of structural information regarding the A 1 AR allosteric site and mechanisms governing cooperativity with orthosteric ligands. We combined alanine-scanning mutagenesis of the A 1 AR second extracellular loop (ECL2) with radioligand binding and functional interaction assays to quantify effects on allosteric ligand affinity, cooperativity and efficacy.
Docking and molecular dynamics (MD) simulations were performed using an A 1 AR homology model based on an agonist-bound A 2A AR structure. Substitution of E172 ECL2 for alanine reduced the affinity of the allosteric modulators, PD81723 and VCP171, for the unoccupied A 1 AR. Residues involved in cooperativity with the orthosteric agonist, NECA, were different between PD81723 and VCP171; positive cooperativity between PD81723 and NECA was reduced upon alanine substitution of a number of ECL2 residues, including E170 ECL2 , and K173 ECL2 , whereas mutation of W146 ECL2 and W156 ECL2 decreased VCP171 cooperativity with NECA. Molecular modeling localized a likely allosteric pocket for both modulators to an extracellular vestibule that overlaps with a region utilized by orthosteric ligands as they transit into the canonical A 1 AR orthosteric site.
MD simulations confirmed a key interaction between E172 ECL2 and both modulators. Bound
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Introduction G protein-coupled receptors (GPCRs) account for approximately 30% of the targets of prescription medicines (Overington et al., 2006) . The majority of these medicines act at the endogenous agonist (orthosteric) site, however in many cases, orthosteric-based drug discovery remains suboptimal owing to lack of sufficient selectivity between related GPCR subtypes (May et al., 2007b) . One promising approach for achieving greater selectivity is to target topographically distinct allosteric sites on GPCRs (Christopoulos, 2002; May et al., 2007b; Wootten et al., 2013) . Allosteric ligands have the potential to modulate the binding and/or signaling properties of an orthosteric ligand, and/or modulate GPCR activity even in the absence of orthosteric ligand (May and Christopoulos, 2003; Christopoulos, 2014) . Allosteric regions typically display greater sequence divergence across the GPCR subtypes; enabling greater subtype selectivity when compared to the orthosteric domains.
An additional advantage is that many allosteric modulators can selectively "tune" tissue responses either up or down when and where the endogenous agonist is present. This type of spatial and temporal specificity of action that can be achieved with allosteric modulators is unattainable with orthosteric ligands, which continuously stimulate or inhibit receptor function where and when they are present (Christopoulos and Kenakin, 2002; May et al., 2007b) .
The endogenous nucleoside, adenosine, acts via four adenosine GPCRs (ARs), the A 1 AR, A 2A AR, A 2B AR, and A 3 AR (Fredholm et al., 2001) . The highly subtype selective A 1 AR allosteric ligand,
, was the first synthetic positive allosteric modulator (PAM) of GPCR agonist function identified ( Fig. 1 ) May et al., 2010; Hill et al., 2014) . The utility of A 1 AR PAMs has been demonstrated in the kidney (Park et al., 2012) , heart Valant et al., 2010) and neurons (Pan et al., 2001; Imlach et al., 2015) , suggesting that A 1 AR PAMs provide a promising therapeutic avenue to treat renal and myocardial ischemia-reperfusion injury and chronic neuropathic pain. Given their therapeutic potential, numerous studies have investigated This article has not been copyedited and formatted. The final version may differ from this version. the structure-activity relationships of A 1 AR PAMs, predominantly exploring derivatives based on the 2-amino-3-benzoylthiophene scaffold (Romagnoli et al., 2015) . However, despite extensive derivation and interrogation of this core scaffold for over two decades, existing A 1 ARs PAMs display largely low affinity, low cooperativity and generally poor solubility.
Alternative approaches, such as structure-based studies, are thus required to assist the design of more potent, selective and efficacious A 1 AR modulators. The recent high-resolution A 2A AR crystal structures in both antagonist-and agonist-bound conformations have facilitated the generation of A 1 AR homology models (Jaakola et al., 2008; Xu et al., 2011; Doré et al., 2011; Lebon et al., 2011) . However, there remains a relative paucity of information regarding the location of the A 1 AR allosteric site. This reflects key challenges associated with structure-function analyses of allostery, because the observed effect of any modulator in the presence of orthosteric ligand reflects a composite of at least three molecular properties: the affinity of the modulator for the unoccupied receptor, the cooperativity between the modulator and the orthosteric ligand when both are present, and the potential intrinsic signaling efficacy of each ligand; these properties can be governed by separate structure-activity and structure-function relationships (Christopoulos, 2014) . Surprisingly, to date, only two structure-function studies have attempted to map the A 1 AR allosteric site, both of which implicated the second extracellular loop (ECL2) of the A 1 AR (specifically residues W156 ECL2 , E164 ECL2 , S150 ECL2 and M162 ECL2 ) in A 1 AR PAM activity (Peeters et al., 2012; Kennedy et al., 2014) . However, neither study explicitly addressed which residues governed modulator affinity relative to transmission of cooperativity or direct allosteric agonism.
Nonetheless, this work clearly highlighted ECL2 as important in the actions of the subtype selective 2-amino-3-benzoylthiophene A 1 AR allosteric modulators, as this region is the least conserved in both sequence and length across the AR subtypes.
In our accompanying article (Nguyen et al., 2016) , we demonstrated that ECL2 can significantly This article has not been copyedited and formatted. The final version may differ from this version. influence orthosteric agonist and antagonist pharmacology. Furthermore, ECL2 is involved in the "transit" of agonists into the orthosteric site within the transmembrane (TM) domains. Herein we assessed the influence of select A 1 AR-ECL2 alanine mutations on the affinity, cooperativity and efficacy of the well-characterized allosteric enhancer, PD81723, and a more recent derivative, VCP171 ((2-amino-4-(3-(trifluoromethyl)phenyl)thiophen-3-yl)(phenyl)methanone) ( Fig. 1 ) (Aurelio et al., 2009b) . We find that ECL2 contributes to a common allosteric pocket in the extracellular vestibule that overlaps with the transit pocket utilized by orthosteric ligands, identify E172 ECL2 as a vital residue for modulator affinity, and highlight how different residues can mediate cooperativity and direct agonism in a manner that can vary with the nature of the allosteric or orthosteric ligand under investigation.
This article has not been copyedited and formatted. The final version may differ from this version. 
Materials and Methods

Materials
VCP171 was synthesized as described previously (Aurelio et al., 2009b; Valant et al., 2014) . PD81723 was synthesized as described previously (Aurelio et al., 2009a) . All other reagents were obtained from suppliers described in the accompanying article (Nguyen et al., 2016) .
Receptor Mutagenesis, Transfection, Cell Culture and Receptor Expression
Receptor mutagenesis, transfection, cell culture and measurement of cell surface expression of wild-type (WT) and mutant human A 1 ARs containing a triple human influenza hemagglutinin (HA) N-terminal tag (3xHA-A 1 ARs) was performed as described in our accompanying article (Nguyen et al., 2016) .
Whole cell radioligand binding washing twice with 100 μL cold phosphate buffered saline (PBS)/well, followed by the addition of 100 μL OptiPhase Supermix™ scintillation cocktail and bound radioactivity was measured using a MicroBeta 2 ™ plate counter (PerkinElmer).
Inhibition of cAMP accumulation
This article has not been copyedited and formatted. The final version may differ from this version. Inhibition of cAMP accumulation was assessed as described previously Following a 30 min incubation at 37°C, the reaction was terminated by rapid removal of buffer and the addition of 50 μ L of ice-cold ethanol. Following ethanol evaporation, detection was performed as outlined previously Vecchio et al., 2016) .
Data Analysis
Data were analyzed using nonlinear regression analysis software (GraphPad Prism 6.0).
Equilibrium binding interaction experiments were fitted to the following allosteric ternary complex model : and VCP171, in a cAMP accumulation assay were globally fitted to the following operational model of allosterism (Leach et al., 2007) :
where E m is the maximal cellular response, K A and K B are the equilibrium dissociation constants of NECA (A) and the allosteric ligand (B), respectively, τ A and τ B are operational measures of NECA and allosteric ligand efficacy, respectively, α is the binding cooperativity factor and β denotes the magnitude of the allosteric effect on orthosteric agonist efficacy, and n is the slope of the transducer function that links occupancy to response. Orthosteric agonist and allosteric ligand affinity were constrained to values determined from radioligand binding (Table 1 and accompanying article).
Efficacy parameters (τ A and τ B ) were corrected for differences in receptor expression between mutants by using the B max values determined from saturation binding assays to scale the efficacy (τ) parameters to that of the wild type receptor (Gregory et al., 2010) . All data preferentially fitted to a transducer slope (n) equal to 1, as determined by an extra-sum-of-squares (F test).
All values of potency, affinity, efficacy and cooperativity were estimated as logarithms (Christopoulos, 1998) . Statistical analysis was performed using a one-way analysis of variance with a Dunnet's post-hoc test to determine differences between the WT and mutant 3xHA-A 1 AR mutants. Statistical significance was defined as P < 0.05.
Homology Modeling, Docking and Molecular Dynamics Simulations
The generation of the active-like homology model of the A 1 AR based on the agonist-bound human This article has not been copyedited and formatted. The final version may differ from this version. A 2A AR (PDB ID 3QAK) was described in our accompanying article (Nguyen et al., 2016) . The ICM Pocket Finder algorithm was used to predict potential ligand binding sites, and NECA, PD81723 and VCP171 were docked using ICM version 3.8.0 (with default parameters) Abagyan and Kufareva, 2009 ). The top scoring docking conformation for each ligand was selected and prepared for MD simulations. MD simulations of the final complex were carried out with the NAMD 2.10 (Phillips et al., 2005) package using the 3-site rigid water TIP3P model, CHARMM27 (MacKerell et al., 1998; Mackerell et al., 2004) , and CGenFF (Vanommeslaeghe et al., 2010; Yu et al., 2012) v.3.0.1 force fields as described previously (Aksimentiev et al., 2012; Shonberg et al., 2013) . The particle mesh Ewald (PME) (Essmann et al., 1995) method was used to evaluate electrostatic interactions. Each system contained an A 1 AR, NECA and either PD81723 or VCP171, in the presence of a lipid bilayer composed of ~220 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) molecules generated using the membrane plugin of the VMD software (v1.9.2) (Humphrey et al., 1996) , and ~15800 water molecules. Sodium and chloride ions were added to neutralize the system, with extra NaCl added to reach a final concentration of 150 mM (~35 sodium ions, ~48 chloride ions). MD energy minimization, equilibration and the production run were performed as described within the accompanying manuscript. VMD v1.9.2 was used for the visualization and analysis of the residue-ligand contacts through the course of each simulation using in-house scripts.
Results
Expression of human A 1 AR ECL2 alanine mutants
As reported in our accompanying article that investigated the role of ECL2 on orthosteric ligand pharmacology (Nguyen et al., 2016) , each residue within ECL2 was substituted for alanine, with the exception of C169 ECL2 , which is known to form an important disulfide bond with C80 3.35 in TM3. Superscripts refer to Ballesteros-Weinstein residue numbering (Ballesteros and Weinstein, 1995 (Nguyen et al., 2016) , although the 3xHA-A 1 AR containing the alanine substitution of F171 ECL2 was expressed to similar levels as the WT (Supplemental Fig.1 of accompanying manuscript), orthosteric ligand binding and function could not be detected and therefore this mutation was not investigated in the current study.
The influence of A 1 AR-ECL2 alanine substitutions on allosteric ligand affinity and cooperativity
Whole cell [ 3 H]DPCPX interaction binding assays in the absence and presence of increasing concentrations of the orthosteric agonist, NECA, and allosteric ligands were performed at WT and mutant 3xHA-A 1 AR ( Fig. 2A & B) . Fitting of these data to an allosteric ternary complex model allowed estimation of allosteric ligand affinity (pK B ) and binding cooperativity (logα I ) between the allosteric ligand and orthosteric agonist ( unoccupied receptor, and enhanced the affinity of NECA approximately 4-8 fold, depending on the PAM. The only mutation that resulted in a significant decrease in the affinity of PD81723 and VCP171 for the free (unoccupied) receptor was E172 ECL2 A (Fig. 3) . Indeed, E172 ECL2 A was the only ECL2 mutation to significantly influence VCP171 affinity, albeit to a lesser extent than PD81723 (Fig. 3B) . In contrast, an increase in the affinity of PD81723 was observed upon alanine substitution of nine residues, N147 ECL2 , N148 (Fig. 3A) . With the exception of G160 ECL2 , each of these mutations was also associated with a concurrent increase in PD81723 affinity. With respect to VCP171, alanine substitution of two tryptophan residues, W146 ECL2 and W156 ECL2 , caused a significant decrease in the binding cooperativity between VCP171 and NECA, with no significant effect on VCP171 affinity (Fig. 3B ). For comparison, the composite parameter, logα I +pK B , which reflects the affinity of each modulator on the NECA-occupied receptor, is also shown in Table 1, where it can be seen that far more subtle effects of each mutation would be concluded if the individual contributions of amino acids to the affinity for the unoccupied receptor relative to cooperativity were not evaluated.
The influence of ECL2 alanine substitutions on allosteric ligand efficacy and functional cooperativity with NECA
Functional interaction assays in the absence and presence of increasing concentrations of orthosteric agonist and/or allosteric ligands were performed at WT and mutant 3xHA-A 1 AR (Fig. 2C & D) .
This article has not been copyedited and formatted. The final version may differ from this version. (Vecchio et al., 2016) , no evidence for constitutive activity was apparent for wild-type or mutant A 1 ARs (unpublished results).
In the absence of orthosteric agonist, both PD81723 and VCP171 behaved as allosteric partial agonists at the WT 3xHA-A 1 AR, mediating an increase in the inhibition of forskolin-stimulated cAMP accumulation (Fig. 2C, D) . Analysis of interaction experiments between increasing concentrations of each modulator and NECA found that residues involved in the transmission of direct allosteric ligand efficacy (τ B(C) ) were relatively conserved between PD81723 and VCP171. A significant decrease in the efficacy of PD81723 and VCP171 was observed at N148 ECL2 A,
E153 ECL2
A, S161 ECL2 A and I167 ECL2 A (Fig. 3) . A five-to ten-fold decrease in efficacy of PD81723
and VCP171 was also observed at R154 ECL2 A and I175 ECL2 A, however this only reached significance for VCP171 (Fig. 3) . Both PAMs enhanced NECA potency at the WT 3xHA-A 1 AR approximately 4-fold. Interestingly, while E172 ECL2 A caused a small increase in the functional cooperativity (logαβ) between PD81723 and the agonist (Fig. 3A) , the remaining mutations had no significant effect. For VCP171, two clusters of ECL2 mutations caused a small but significant decrease in VCP171 functional cooperativity. The first cluster involved R154 ECL2 A, W156 ECL2 A and N159 ECL2 A, and the second involved V174 ECL2 A and I175 ECL2 A (Fig. 3B) . These results may suggest a divergence in the influence of the mutations on cooperativity with NECA at the level of binding affinity (α) versus efficacy (β). However, evaluation of log(β) values found no significant difference from the WT, with the exception of the influence of S161 ECL2 A on PD81723, suggesting This article has not been copyedited and formatted. The final version may differ from this version. that the observed cooperativity between NECA and the modulators is largely driven by changes in binding cooperativity (α) (Supplemental Fig. 1A ).
Molecular modeling of the A 1 AR allosteric site
As described in the accompanying manuscript (Nguyen et al., 2016) , an "active-like" homology model of the human A 1 AR was generated based on the agonist ( , E172 ECL2 and N254 6.55 (Fig. 6A ).
Within the extracellular vestibule, PD81723 was predicted to form hydrogen bonds with E172
ECL2
with the highest frequency compared to the other residues ( Fig. 7 ; Data Supplement 1), which correlates well with the significant reduction in PD81723 affinity observed for the E172 ECL2 A This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 7C) . PD81723 was also flanked by a hydrogen bond with the side chain of another glutamic acid residue, E170 ECL2 (Fig. 7B ). This residue was found to reside within 3.5 Å of PD81723 for greater than 20% of total MD time in two of the six simulations (Fig. 6A ). Our molecular modeling predicted a network of hydrogen bond interactions between residues within the extracellular vestibule surrounding the allosteric binding pocket (Fig. 7B ). These include a hydrogen bond between E172 ECL2 and K265 ECL3 as well as a hydrogen bond between the side chain of E170 ECL2 and two lysine residues K168 ECL2 and K173 ECL2 (Fig. 7B) . Our mutagenesis results suggest that both E170 ECL2 and K173 ECL2 are involved in the transmission of PD81723 binding cooperativity (Fig. 7D ). As such, in addition to stabilizing the A 1 AR extracellular structure, the putative network of hydrogen bond interactions within the extracellular vestibule may have a role in the transmission of cooperativity between the extracellular and orthosteric binding sites. ECL2
residues located within 3.5 Å of VCP171 during the 40 ns MD simulations include F171 ECL2 and E172 ECL2 (Fig. 6B ). Similar to PD81723, VCP171 was stabilized in the allosteric pocket via a hydrogen bond with E172 ECL2 , the only residue for which a significant reduction in VCP171 affinity was observed upon mutation to alanine ( Fig. 8 (Voigtlander et al., 2003; Avlani et al., 2007; Jäger et al., 2007; Narlawar et al., 2010; Nawaratne et al., 2010; Peeters et al., 2012; Abdul-Ridha et al., 2014) . As such, the aim of the current study was to delineate the role of ECL2 in A 1 AR allosteric ligand pharmacology. We performed an alanine scan of ECL2 and quantified the effect of mutations on allosteric ligand affinity, efficacy and cooperativity. Ligand docking and MD simulations were subsequently performed to assist with the interpretation of our findings. A negatively charged amino acid, E172 ECL2 was identified as a key ECL2 residue involved in the binding of two allosteric ligands, PD81723 and VCP171 to the unoccupied receptor. ECL2
was also found to be essential for the transmission of cooperativity and for direct allosteric ligand intrinsic efficacy.
To date, only a few studies have attempted to map the A 1 AR allosteric site. Two recent structurefunction studies implicated ECL2 (Peeters et al., 2012; Kennedy et al., 2014) , however neither study differentiated residues involved in allosteric binding affinity versus cooperativity or efficacy. Peeters et al. (2012) suggested alanine substitution of W156 ECL2 decreased PD81723 allosteric activity. Our results suggest that the mechanism behind this effect is because W156 ECL2 is one of two tryptophan residues involved in mediating binding cooperativity between A 1 AR PAMs and orthosteric agonists, in our case specifically between VCP171 and NECA (Fig. 8D, Fig. 8F ). The recent high-resolution crystal structure of an active human M 2 muscarinic acetylcholine receptor This article has not been copyedited and formatted. The final version may differ from this version. bound to both an orthosteric agonist and PAM identified extensive π-π stacking interactions between the aromatic ring of the PAM and aromatic residues in ECL2 and the top of TM7 (Kruse et al., 2013) . Similar π-π stacking interactions may occur between the aromatic rings of VCP171 and the tryptophan residues W156 ECL2 and W146 ECL2 in the A 1 AR-ECL2, however long time-scale MD simulations may be required to observe such interactions. A second study by Kennedy et al. (2014) combined alanine scanning and radioligand dissociation kinetic assays with molecular modeling and observed a significant decrease in A 1 AR PAM, ATL525 (2-amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl) biphenyl-4-yl-methanone), activity at two constructs containing alanine mutations within ECL2: N147+N148+L149+S150 and N159+G160+S161+M162. In agreement with these results, we observed a significant decrease in the binding cooperativity between PD81723 and NECA upon single alanine substitution of N147 ECL2 , N148 ECL2 , G160 ECL2 or S161 ECL2 . In contrast with our results, Kennedy et al (2014) identified S150 ECL2 and M162 ECL2 as key residues involved in conferring allosteric activity of ATL525. However, we have shown that the residues involved in the transmission of allosteric cooperativity appear to be probe-dependent.
This probe dependence may be due to actual differences in binding modes/poses or, as suggested by our current work, due to differences in the transmission of cooperativity from a "common" allosteric binding domain.
The combination of our mutational and computational data suggests that E172 ECL2 is a key residue involved in binding of both PD81723 and VCP171 to the non-agonist-occupied A 1 AR. The putative allosteric site was bordered by E172 ECL2 . The 2-amino and 3-keto group of PD81723 and VCP171
were predicted to form hydrogen bond interactions with E172 ECL2 during MD simulations of cobound orthosteric and allosteric ligands; both the 2-amino and 3-keto groups are known to be required for A 1 AR allosteric ligand activity Kennedy et al., 2014) . Of particular note, this proposed allosteric binding pocket, supported by our experimental findings and MD, overlaps with the "transition site" within the extracellular vestibule proposed for the orthosteric This article has not been copyedited and formatted. The final version may differ from this version. agonist, NECA, and partially overlaps with the binding site of the orthosteric antagonist, DPCPX, in our accompanying manuscript (Nguyen et al., 2016) . This finding may explain prior studies where relatively subtle structural changes in A 1 AR molecules can convert allosteric modulators into compounds with apparently orthosteric pharmacology, i.e., these changes can alter the thermodynamic properties that favor recognition of one pocket over the other Valant et al., 2012) . Furthermore, the predicted partial overlap between the putative allosteric pocket and DPCPX provides a potential mechanism to explain the previously proposed competitive interaction between A 1 AR allosteric modulators and orthosteric antagonists , as well as our findings of an inhibitory interaction between either PD81723 or VCP171 with
Prior studies of the M 2 muscarinic acetylcholine receptor also identified a role for charged residues within ECL2 in the affinity and/or cooperativity of allosteric ligands (Gnagey et al., 1999; May et al., 2007a) . In our study, alanine substitution of the charged A 1 AR ECL2 residues, E170 ECL2 and K173 ECL2 , significantly decreased the positive cooperativity between the NECA and PD81723.
Furthermore, alanine substitution of E172 ECL2 significantly decreased allosteric ligand affinity.
Interestingly, at both the A 1 AR and M 2 receptor, the cluster of charged residues implicated in allosteric ligand binding and/or the transmission of cooperativity is proximal to the conserved cysteine residue within ECL2 that forms a disulfide bond with TM3. Furthermore, our molecular modeling suggests multiple negatively charged glutamic acid and positively charged lysine residues located within the extracellular vestibule are involved in a network of hydrogen bonds. During MD simulations, the side chain of E170 ECL2 forms a hydrogen bond with PD81723 and the side chain of two adjacent lysine residues, K168 ECL2 and K173 , N148 ECL2 , G160 ECL2 and S161 ECL2 . Glycine is the smallest amino acid due to the lack of a side chain. Consequently, this amino acid has the greatest conformational flexibility, a mobility that may be required for the transmission of cooperativity. The polar asparagine and serine residues implicated in the transmission of cooperativity are located relatively far from the predicted allosteric site, and therefore likely have indirect effects. Alternatively, the middle section of ECL2 may form a lid over the allosteric binding site and stabilize the conformation of the allosteric pocket. However, such large-scale movements are unlikely to be observed during the 40 ns MD simulations.
Nonetheless, the use of analytical approaches that differentiate mutational effects on modulator affinity from those that govern allosteric efficacy or that mediate the transmission of cooperativity with orthosteric ligands raises at least two key issues for future consideration, both related to the role of the transition of the unliganded receptor to a bound active state. The first issue is exemplified by the decrease in signaling efficacy of both PD81723 and VCP171 upon alanine substitution of N148 ECL2 , E153 ECL2 , R154 ECL2 , S161
, I167 ECL2 or I175 ECL2 . In our accompanying article (Nguyen et al., 2016) , a significant decrease in the efficacy of the orthosteric agonist, NECA, was also observed at the N148 ECL2 A, E153
A and R154 ECL2 mutations, suggesting that these residues are part of a "global" activation mechanism irrespective of the "trigger" (i.e., allosteric or orthosteric). In contrast, S161 ECL2 , I167 ECL2 and I175 ECL2 appear to be exclusively involved in the transmission of allosteric but not orthosteric ligand efficacy. The paradigm of global versus allosteric modulator-specific activation mechanisms has been reported for other receptors (e.g., Nawaratne et al., 2010) . The second key issue relates to mechanisms underlying the transmission of cooperativity. Although our mutational analysis of modulator affinity was determined explicitly within the context of the free receptor, changes in cooperativity reflect effects on the ternary This article has not been copyedited and formatted. The final version may differ from this version. complex of agonist-receptor-modulator. It is likely that the nature of the allosteric pocket changes dramatically between the two states; this would not be captured by the ground state K B value, but would be subsumed in the cooperativity values. Thus, the hydrogen bond networks implicated as playing a role in the transmission of allostery may be part of a larger, more dynamic, network that reflects receptor transition between states, and to which ECL2 contributes an important role. This can also explain why some of the residues that have a significant effect on ligand pharmacology, particularly signaling efficacy or cooperativity, need not be in the immediate vicinity of any predicted binding pocket.
In conclusion, the current study has provided new insights into the location of the A 1 AR allosteric site, as well as residues involved in the transmission of allosteric cooperativity and efficacy.
Residues involved in allosteric ligand binding and efficacy were conserved between the two allosteric ligands assessed, whereas residues involved in the transmission of allosteric cooperativity were distinct. The delineation of ECL2 residues involved in allosteric ligand affinity, cooperativity and efficacy provided within this study may facilitate future structure-function studies of the A 1 AR allosteric site and assist structure-based design of novel A 1 AR allosteric ligands.
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